Unknown

Dataset Information

0

Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.


ABSTRACT: Epigenetic targeting has emerged as an efficacious therapy for hematological cancers. The rare and incurable T-cell prolymphocytic leukemia (T-PLL) is known for its aggressive clinical course. Current epigenetic agents such as histone deacetylase (HDAC) inhibitors are increasingly used for targeted therapy. Through a structure-activity relationship (SAR) study, we developed an HDAC6 inhibitor KT-531, which exhibited higher potency in T-PLL compared to other hematological cancers. KT-531 displayed strong HDAC6 inhibitory potency and selectivity, on-target biological activity, and a safe therapeutic window in nontransformed cell lines. In primary T-PLL patient cells, where HDAC6 was found to be overexpressed, KT-531 exhibited strong biological responses, and safety in healthy donor samples. Notably, combination studies in T-PLL patient samples demonstrated KT-531 synergizes with approved cancer drugs, bendamustine, idasanutlin, and venetoclax. Our work suggests HDAC inhibition in T-PLL could afford sufficient therapeutic windows to achieve durable remission either as stand-alone or in combination with targeted drugs.

SUBMITTER: Toutah K 

PROVIDER: S-EPMC8237267 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC5504819 | biostudies-other
| S-EPMC7585232 | biostudies-literature
| S-EPMC10419310 | biostudies-literature
| S-EPMC5802577 | biostudies-literature
| S-EPMC5582236 | biostudies-literature
| S-EPMC4807901 | biostudies-literature
2014-05-29 | E-MTAB-1991 | biostudies-arrayexpress
| S-EPMC7570784 | biostudies-literature
| S-EPMC4148768 | biostudies-literature
| S-EPMC10601740 | biostudies-literature